FDA accepts Alvotech’s AVT16 filing as Entyvio biosimilar race builds

Alvotech has cleared an important regulatory checkpoint in the US biosimilars market. On June 8, 2026, the company said the FDA accepted for review its BLA for AVT16, a proposed interchangeable biosimilar to Takeda’s Entyvio (vedolizumab), formulated as an intravenous lyophilized vial. If approved, AVT16 would enter a market where no FDA-approved vedolizumab biosimilar has yet appeared, making the filing notable both for timing and for Alvotech’s decision to pursue an interchangeability designation from the outset. (globenewswire.com)

The filing follows a broader push by Alvotech to deepen its immunology portfolio. In its recent Q1 2026 update, the company said it had already submitted a marketing authorization application to the European Medicines Agency for AVT16 and AVT80, its subcutaneous vedolizumab biosimilar candidate. Company disclosures in its annual reporting also show that AVT16’s development path changed in late 2025, when Alvotech discontinued a global confirmatory patient study after determining that study would not be required for dossier submission, adding that the decision was not related to safety. (investors.alvotech.com)

Alvotech’s June 8 announcement adds several useful specifics. The company said the FDA filing is for AVT16 as a proposed interchangeable biosimilar to Entyvio for IV administration, and that a pivotal pharmacokinetic study announced in February 2026 for AVT80 is considered, based on regulatory advice, pivotal to support the demonstration of clinical similarity for both AVT16 and AVT80. That matters because it suggests Alvotech is trying to leverage a shared development package across formulations, potentially improving efficiency as it competes in a biologics category that has remained insulated from US biosimilar competition so far. (globenewswire.com)

The commercial backdrop helps explain the interest. Takeda has described Entyvio as its top-selling product in the fiscal year ended March 31, 2025, and reported continued growth for the brand in subsequent investor materials. Independent market landscape materials have also pointed to 2027 as a key period for expected US vedolizumab biosimilar entry, though actual launch timing can still depend on patent, exclusivity, and litigation dynamics, not just FDA review. That means BLA acceptance is meaningful, but it’s still only one step in a longer path to commercialization. (sec.gov)

Direct outside expert reaction to this specific filing was limited in early coverage, but the broader policy context is clear. FDA says biosimilar approvals can improve access by increasing the number of medication options and potentially lowering costs. At the same time, interchangeability carries additional practical significance because, under US rules, an interchangeable biosimilar may be substituted at the pharmacy level without prescriber intervention, subject to state law. That point is especially relevant in chronic diseases like ulcerative colitis and Crohn’s disease, where continuity of therapy, payer management, and site-of-care decisions all affect uptake. (fda.gov)

Why it matters: For veterinary professionals, this is a human-drug regulatory story, but it still has signal value. Biosimilar regulation in human medicine often shapes expectations in adjacent sectors around manufacturing comparability, naming, substitution policy, reimbursement pressure, and pet parent demand for lower-cost biologic care. Alvotech’s strategy also reflects a broader industry pattern: companies are no longer just chasing biosimilarity, they’re building regulatory and supply strategies around interchangeability, multiple formulations, and global filings. (globenewswire.com)

There’s also an operational angle. Alvotech has been managing manufacturing and regulatory execution across several programs at once, including a new US-based second source supply agreement with Fujifilm Biotechnologies announced in May 2026. For veterinary teams watching biologics more broadly, that’s a reminder that product success depends not just on clinical data, but on inspection readiness, supply resilience, and the ability to support launches across markets. (investors.alvotech.com)

What to watch: The near-term questions are whether the FDA sets a clear review timeline, whether AVT16 reaches approval before rival vedolizumab biosimilars, and whether patent or market-access barriers push any eventual US launch closer to 2027 or beyond. (globenewswire.com)